Latest Articles

Publication Date
All News Scientific
Giorgio Bogani: New Insights into POLE-Mutated Endometrial Cancer with Nodal Involvement - Oncodaily

Giorgio Bogani: New Insights into POLE-Mutated Endometrial Cancer with Nodal Involvement Oncodaily

Published: Oct. 18, 2025, 10:08 p.m.
Read Full Article
Minister Apologizes for Endometriosis Treatment Delays and Introduces New Framework - Emegypt

Minister Apologizes for Endometriosis Treatment Delays and Introduces New Framework Emegypt

Published: Oct. 18, 2025, 9:47 p.m.
Read Full Article
HSE Chief Bernard Gloster Announces New Endometriosis Plan to Enhance Surgical Care Access - Emegypt

HSE Chief Bernard Gloster Announces New Endometriosis Plan to Enhance Surgical Care Access Emegypt

Published: Oct. 18, 2025, 8:37 p.m.
Read Full Article
Endometriosis framework launched 18 months late but promises major improvements in women’s care - Irish Examiner

Endometriosis framework launched 18 months late but promises major improvements in women’s care Irish Examiner

Published: Oct. 18, 2025, 3 p.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti - PharmiWeb.com

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti PharmiWeb.com

Published: Oct. 18, 2025, 1:03 p.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - Lelezard

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Lelezard

Published: Oct. 18, 2025, 12:47 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - The AI Journal

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer The AI Journal

Published: Oct. 18, 2025, 10:20 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational - GlobeNewswire

Genmab Announces New Data Demonstrating Investigational GlobeNewswire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - GlobeNewswire

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer GlobeNewswire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!